Dashboard
Manage Tickers

ARQTArcutis Biotherapeutics, Inc.

Nasdaq arcutis.com


$ 7.48 $ 0.01 (0.07 %)    

Tuesday, 11-Jun-2024 11:05:45 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 464.79 $ 1.29 (0.28 %)
DIA $ 387.34 $ -0.03 (-0.01 %)
SPY $ 534.21 $ 0.13 (0.02 %)
TLT $ 91.04 $ -0.01 (-0.02 %)
GLD $ 214.09 $ -0.33 (-0.16 %)
$ 7.54
$ 7.47
$ 0.00 x 0
$ 7.46 x 100
$ 7.41 - $ 7.57
$ 1.76 - $ 13.17
2,130,720
na
837.31M
$ 0.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-22-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-19-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

arcutis-presents-new-long-term-data-of-roflumilast-cream-015-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-adults-and-children-down-to-age-6-at-the-revolutionizing-alopecia-areata-vitiligo-and-eczema-conference
Arcutis Presents New Long-Term Data Of Rof...
06/10/2024 18:32:07

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through ...

arcutis-reports-multiple-abstracts-including-oral-presentation-at-the-revolutionizing-alopecia-areata-vitiligo-and-eczema-conference-from-june-8-10-2024
Arcutis Reports Multiple Abstracts, Includ...
06/05/2024 12:07:36

New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be...

why-bolt-biotherapeutics-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Bolt Biotherapeutics Shares Are Tradin...
05/15/2024 17:38:38

needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-18
Needham Maintains Buy on Arcutis Biotherap...
05/15/2024 15:51:18

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

nextracker-posts-upbeat-earnings-joins-mondaycom-nu-holdings-and-other-big-stocks-moving-higher-on-wednesday
NEXTracker Posts Upbeat Earnings, Joins mo...
05/15/2024 14:21:59

Core News & Articles
Market-Moving News for May 15th
05/15/2024 12:33:09

EDBL: 87% | Edible Garden shares are trading higher. The company reported Q1 financial results. MNDY: 22% | Monday.com shares ...

why-arcutis-biotherapeutics-shares-are-trading-higher-by-29-here-are-20-stocks-moving-premarket
Why Arcutis Biotherapeutics Shares Are Tra...
05/15/2024 12:14:56

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
05/15/2024 12:06:56

mizuho-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-18
Mizuho Maintains Buy on Arcutis Biotherape...
05/15/2024 11:09:02

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $17 to $18.

arcutis-biotherapeutics-stock-climbs-after-blockbuster-q1-results
Arcutis Biotherapeutics Stock Climbs After...
05/14/2024 21:11:26

Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 20:31:13

arcutis-biotherapeutics-q1-2024-adj-eps-032-beats-073-estimate-sales-4957m-beat-1468m-estimate
Arcutis Biotherapeutics Q1 2024 Adj EPS $0...
05/14/2024 20:02:30

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate ...

the-journal-of-clinical-and-aesthetic-dermatology-published-arcutis-biotherapeutics-outcomes-of-a-comprehensive-evaluation-by-an-expert-dermatologist-panel-assessing-the-formulation-ingredients-of-zoryve-topical-foam-03
The Journal Of Clinical And Aesthetic Derm...
05/13/2024 12:08:22

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin...

evaluating-arcutis-biotherapeutics-insights-from-5-financial-analysts
Evaluating Arcutis Biotherapeutics: Insigh...
04/12/2024 12:00:53

needham-reiterates-buy-on-arcutis-biotherapeutics-maintains-16-price-target
Needham Reiterates Buy on Arcutis Biothera...
04/12/2024 10:44:55

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.

arcutis-appoints-david-topper-as-chief-financial-officer
Arcutis Appoints David Topper As Chief Fin...
04/10/2024 12:05:37

eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday
EQT, Genie Energy And Other Big Stocks Mov...
03/11/2024 14:37:32

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

sunday-arcutis-biotherapeutics-new-data-from-integument-ped-phase-3-study-of-roflumilast-cream-in-children-2-to-5-years-with-mild-to-moderate-atopic-dermatitis-showed-significant-improvements-across-multiple-efficacy-endpoints-and-all-timepoints
Sunday, Arcutis Biotherapeutics' New Data ...
03/11/2024 09:11:57

arcutis-announces-acceptance-of-late-breaking-abstract-in-atopic-dermatitis-among-five-new-topical-roflumilast-data-being-presented-at-the-american-academy-of-dermatology-annual-meeting
Arcutis Announces Acceptance Of Late Break...
03/04/2024 13:18:25

Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages ...

arcutis-prices-150m-public-offering-of-15789474-common-shares-at-950share
Arcutis Prices $150M Public Offering Of 15...
02/29/2024 08:00:02

The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)